Bristol Myers Squibb Q3 FY26: where the revenue came from and where it went
The whole income statement of Bristol Myers Squibb for this quarter, as one diagram: what earned the revenue, and what it went on.
- Period
- Jul 1 – Sep 30, 2026
- Reported
- Oct 29, 2026
Revenue$13.07B
+7% year over year
Gross profit$8.92B
68% margin
Operating profit−$0.37B
−3% margin
Net profit$2.16B
17% margin
Net profit is larger than what operations earned, because the statement adds $2.91B below it, under Other income, net.
The numbers
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 13.07 | 100% | +7% |
| Eliquis | 4.69 | 36% | +25% |
| Opdivo | 2.37 | 18% | |
| Other revenue | 2.29 | 17% | |
| Orencia | 0.98 | 7% | |
| Yervoy | 0.79 | 6% | |
| Reblozyl | 0.75 | 6% | |
| Other growth brands | 0.73 | 6% | |
| Alliance & other | 0.46 | 4% | |
| Cost of revenue | −4.15 | 32% | |
| Gross profit | 8.92 | 68% margin | −4pp |
| R&D | −2.37 | 18% | −3pp |
| SG&A | −1.70 | 13% | −2pp |
| Other | −5.23 | 40% | |
| Operating profit | −0.37 | −3% margin | |
| Other income, net | 2.91 | ||
| Tax | −0.37 | ||
| Net profit | 2.16 | 17% margin | −1pp |
1 of 418 companies, most recently reported first
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest